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Abstract. It has been shown that the a4ß1 integrin is
the lymphocyte receptor for the carboxy terminal
cell-binding domain of fibronectin which comprises
adhesion sites in Hep 2 and a high affinity site, CS-1,
in the type III connecting segment or V (for variable)
region. In the present studies, using a series of pep-
tides derived from CS-1, we identify the tripeptide leu-
asp-val (LDV), as the minimal peptide capable of sup-
porting stable lymphocyte or melanoma cell adhesion.
However, only cells which expressed an active form of
the a401 complex were capable of attaching to and
spreading on LDV peptide. On a molar basis, LDV
minimal peptides were either not active or 10-20
times less active than intact CS-1 in promoting the
adhesion of lymphocytes expressing the resting form
of the receptor. In cells which express the high avidity
form of the receptor, LDV and CS-1 were equally
effective in promoting cell adhesion and spreading.
V
4,Rlt)US cell populations can interact with adhesion
sequences in the carboxy terminal cell-binding do-
main (CTCBD) , of fibronectin (McCarthy et al.,
1986; Bernardi et al., 1987; Humphries et al., 1986, 1987;
Liao et al., 1989; Mould et al., 1990; Wayner et al., 1989;
Garcia-Pardo et al., 1990; Guan and Hynes, 1990), in addi-
tion to the arg-gly-asp-set (RGDS) adhesion sequence lo-
cated in the central cell binding domain (CCBD) offibronec-
tin (Pierschbacher and Ruoslahti, 1983). Lymphocytes, in
particular, bind with high affinity to a 38-kD tryptic frag-
ment of fibronectin (Garcia-Pardo et al., 1987; Garcia-Pardo
et al., 1990; Wayner et al., 1989) which contains the Hepa-
rin 2 (Hep 2) domain and 67 (out of 120) amino acid residues
ofthe alternatively spliced type III connecting segment or V
(for variable) region (Schwarzbauer et al ., 1983, 1985 ;
Kornblihtt et al., 1985; Paul et al., 1986). The 67 amino
acids ofthis fragment (Garcia-Pardo et al., 1987)which are
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The avidity of the a4ß l complex could be altered with
mAbs to ßl which specifically activate ßl dependent
function. The high avidity form of the a4ß1 complex
could be induced on U937 cells, T, and B lympho-
blastoid cell lines, or PHAstimulated T cell blasts.
Resting PBL could not be induced to bind LDV pep-
tide conjugates by activating antibodies to ßl implying
that two signals are required for LDV recognition by T
cells. In conclusion, these data show clearly that the
minimal peptide for the a4ß1 complex in CS-1 is the
LDV sequence. Although numerous cell populations
can interact with intact CS-1 only cells which express
an active a4ß1 complex can bind the LDV sequence.
This implies that cell interaction with the carboxy ter-
minal cell-binding domain of fibronectin can be regu-
lated at several levels: (a) a4ß1 expression; (b) activa-
tion of the a4ß1 complex; and (c) alternate splicing of
CS-1 into V+ isoforms of fibronectin.
derived from alternative splicing ofthe fibronectin gene span
the CS-1, CS-2, and CS-3 regions defined by Humphries et
al. (1986, 1987) . Our previous findings indicated that it was
the CS-1 sequence which contributed to the high affinity
binding site for lymphocytes on this fragment (Wayner et al.,
1989; Garcia-Pardo et al., 1990). Interestingly, in human
fibronectin two splice sites exist in V120 cDNA (Kornblihtt
et al., 1985; Paul et al., 1986), one at the COOH-terminal
end of CS-1 and another just NH2-terminal to the CS-5 re-
gion. Therefore, the entire CS-1 region can either be present
or absent in V+ fibronectins. The importance of this with
regard to lymphocyte function is, at present, unknown.
mAb inhibition studies showed that it was the a4ßl inte-
grin receptor which mediated lymphocyte binding to CS-1
(Wayner et al., 1989 ; Garcia-Pardo et al., 1990). This find-
ing was later confirmed by affinity chromatographic isola-
tion of the a4ß1 integrin from hematopoietic and melanoma
cell populations on CS-1 sepharose (Mould et al., 1990;
Guan and Hynes, 1990). Further, it has been reported that
melanoma cells can recognize and bind the LDV sequence
located in the COOH-terminal portion of CS-1 strongly sug-
gesting that LDV is a peptide ligand for a4ß1 (Mould et al .,
1991). However, the minimal sequence in CS-1 capable of
489promoting stable hematopoietic cell adhesion has not yet been
identifiedalthough two recent studies have shown that hema-
topoietic cellscan interact with LDVcontaining peptides de-
rived from the COOH-terminal portion of CS-1 (Garcia-
Pardo et al., 1990; Guan and Hynes, 1990).
In the present paperwe have identifiedthe minimal peptide
ligand in CS-1 that is capable of supporting stable hemato-
poietic cell adhesion via a4ß1 . Surprisingly, this varied ac-
cording to the cell population examined. Although the mini-
mal peptide for melanoma cell adhesion was leu-asp-val (or
LDV), many hematopoietic cell lines required larger por-
tions of the COOH-terminal end of CS-1, while still other
populations could be identifiedthat required the entire length
of CS-1 to form stable attachments. This suggested that the
LDV sequence might be recognizedby some cell populations
only in the context of intact CS-1 and that this recognition
may be regulated in a cell type-specific manner. Further
studies revealed that LDV recognition was in fact determined
by the avidity of the a4ß1 complex expressed by an in-
dividual cell population. The low avidity receptor, expressed
on Jurkat, Ramos, U937, or PHA-activated T cells, couldnot
bind LDV outside the context of CS-1 while the high avidity
receptor, expressed by HUT 78 or A375 melanoma cells,
could directly interact with LDV peptide-coated surfaces.
The avidity of the a4ß1 complex couldbe altered by a mAb
to ßl, 8A2, which up-regulates a4ß1-dependent function
(Kovach et al ., 1992) but not surface expression (thismanu-
script) . Therefore, in the presence of mAb 8A2 hematopoi-
etic cells could be induced to form stable attachments to
LDVcoated surfaces. This suggests that recognition of the
LDV sequence in CS-1 requires activation of the a4ß1 com-
plex. Finally, PHAstimulated but not resting T cells could
be induced by mAb 8A2 to bind LDV suggesting that resting
T cells require an additional signal(s) for LDV recognition.
Together, these data strongly suggest that hematopoietic
cell interaction with the CTCBD of fibronectin is regulated
at several levels: (a) a4ß1 expression; (b) activation of a4ß1;
(c) presence of the CS-1 sequence in V+ fibronectin iso-
forms. Furthermore, these data also suggest that multiple
signals, one of which is transduced through ßl, are required
for T lymphocyte activation and LDV recognition.
Materials andMethods
Materials
Fibronectin was purified from human plasma as previously described
(Wayner and Carter, 1987). Fragments of fibronectin were the same as pre-
viously described (Wayner et al., 1989; Garcia-Pardo et al., 1987). 51Cr-
sodium chromate was from New England Nuclear (Boston, MA). Rabbit
serum albumin(RSA), BSA and protein A-agarosewere from Sigma Chem-
ical Co. (St. Louis, MO). Protein G-agarose was a generous gift from Dr.
Kurt Gehlsen (Pharmacia, La Jolla, CA).
Peptides and Peptide Conjugates
A series of peptides spanning the entire CS-1 region were synthesized by
Drs. Jim Blake and Wes Cosand (Oncogen, Seattle, WA) using an Applied
Biosystems 430A peptide synthesizer and were a generous gift from the
Bristol Myers-Squibb Pharmaceutical Research Institute, Oncogen Divi-
sion (Seattle, WA). Synthetic peptides were HPLC purified and tested for
direct toxicity and growth-inhibitory activity. Some peptides were synthe-
sized with an NH2-terminal cysteine at the end of a gly-gly-gly tail and
were chemically conjugated to SMCC-derivatized RSA for use in cellular
adhesion assays. None of the peptides, either inhibitory or noninhibitory,
or any of the peptide conjugates were toxic or growth inhibitory.
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Cellsand Cell Culture
The A375 (human melanoma) cell line was obtained from Dr. Diane Horn
(Oncogen, Seattle, WA) and the Jurkat (human T lymphoblastoid) cell line
was obtained from Dr. Dave Urdal (Immunex Corp, Seattle, WA). The
HT1080, RD, Ramos, and HUT 78 cells were obtained from the American
Type Culture Collection (Rockville, MD). All cell culture conditions were
as previously described (Wayner and Carter, 1987). PHA-stimulated T cell
blasts were prepared exactly as described from normal fresh human blood
(Wayner et al., 1989).
Monoclonal Antibodies
All mAbs to adhesion receptors were produced and characterized as de-
scribed (Wayner and Carter, 1987; Wayner et al., 1989; Kovach et al.,
1992). The 8A2 mAb has been shown to recognize an epitope on the inte-
grin ßl subunit using the previously described anti-ßl, P400 (Kovach et
al., 1992). The anti-a4 mAb P4C2 has been previously described (Wayner
et al., 1989). In every case, control antibody consisted ofprotein G-purified
nonimmune mouse IgG.
Activation ofßl with Mab 842
The ßl subunit was activated with mAb 8A2 several ways. In some experi-
ments, celladhesionassays were carried out in the presence of 8A2. Inother
experiments, cells were pretreated with 8A2 mAb for 30 min, washed, and
then used in cell adhesion assays. The effects of 8A2 mAb could be mea-
sured within 10 min and as little as 0.1 ug/ml 8À2 could stimulate 01
function.
Inhibition of Cell Adhesion to Intact
FFbronectin and CS-1 Peptide-RSA Conjugates
with MonoclonalAntibodies
Antibodiesthat would altercelladhesion to fibronectin orCS-1 peptide RSA
conjugates were identified as previously described (Wayner and Carter,
1987; Wayneret al., 1989). Briefly, 48-well virgin styreneplates (No. 3547;
Costar, Cambridge, MA) were coated with 5,ug/ml plasma fibronectin, or
peptide conjugate (with the final concentration of peptide being 5 wg/ml).
Na251Cr04-labeled cells were incubated with mAbs to adhesion receptors
for 15 min at room temperature and were then allowed to attach to the
coated substrates in the presence ofthe antibodies for 30-60 min at 37°C.
In some cases antibodies to adhesive ligands were pre-incubated with the
substrates for 15 min before the cells were added. At the end of the incuba-
tion, nonadherent cells were removedby washing withPBSandthe adherent
cells were dissolved in 0.1 N NaOH/0.25% SDS and hound 51Cr cpm were
quantitated in a gamma counter.
Inhibition ofCellAdhesion to FIbronectin with CSI
Derived Peptides
For peptide inhibition studies, 51Cr-labeled cells were pre-incubated with
CS-1-derived peptides at various concentrations for 15 min at room temper-
ature. The cells were then allowed to attach to fibronectin-coated surfaces
in the presence of exogenous peptides for 30-60 min. The assay then
proceeded as described above.
Results
a4ß1 Is the Receptorfor the CSI Sequence
Located in the Carboxy Terminal Cell-binding Domain
ofFYbronectin
We and others have previously reported that antibodies
specific for epitopes on the a4 subunit inhibit T or B lym-
phocyte adhesion to plasma fibronectin, fragments of fibro-
nectin containing adhesion sites in the Hep 2 domain, and
the first 25 amino acids (CS-1) of the V (for variable) region
(Wayner et al ., 1989; Garcia-Pardo et al., 1990; Guan and
Hynes, 1990). Other workers have shown that the conjugate
of a4 with ßl can be affinity purified on immobilized CS-1
490Figure 1. Adhesion of Jurkat T lymphoblastoid cells to plasma
fibronectin, fragments of plasma fibronectin, or CS-1-rsa pep-
tide-coated surfaces in the presence of inhibitory anti-integrin
mAbs . 5'Cr-labeled cells were incubated in the presence of the in-
dicated mAbs (10,ug/ml-purified antibody) for 10 min at ambient
temperature and allowed to attach to the protein or peptide
coated-surfaces for 15-30 min in the presence of the inhibitory
mAbs . Adhesion is expressed as percent of control (protein G-pu-
rified non-immune mouse IgG) . The plasma fibronectin and the
plasma fibronectin fragments are identical to those used and de-
scribed previously (Wayner et al ., 1989) .
(Mould et al., 1990 ; Guan and Hynes, 1990) indicating that
the cellular receptor for CS-1 is a4ß1 . However, the contri-
bution of ßl in mediating adhesion to fragments of fibro-
nectin containing Hep 2 (58 kD derived from the B chain of
plasma fibronectin) or the high affinity CTCBD (38 kD de-
rived from theA chain offibronectin and contains Hep 2 and
CS-1) has not yet been elucidated . Therefore, we examined
the adhesion of T (Jurkat ; Fig . 1) orB (not shown) lympho-
blastoid cell lines to surfaces coated with various fragments
offibronectin in the presence ofmAbs to inhibitory epitopes
on a4 or ßl . The data in Fig . 1 show clearly that Jurkat cell
adhesion to plasma fibronectin, CS-1, or fragments of fibro-
nectin containing Hep 2 (58 kD) and the entire CTCBD (38
kD) can be inhibited by mAbs to a4 (P4C2) or ßl (P4C10) .
This confirms the role of 01 in mediating adhesion of cells
to the Hep 2 site as well as to CS-1 . As we have already
reported, adhesion to the CCBD (80-kD fragment) which
contains the RGDS sequence is inhibited by mAbs directed
to a5 (PID6) or ßl (P4C10) .
Identification ofthe Minimal Peptide Ligandfor
the Lymphocyte a4ß1 Receptor in CS-1
The first step taken to define a minimal peptide ligand in
CS-1 for the a4ß1 integrin receptor was to divide CS-1 into
two smaller peptides, an N112-terminal (A13) and a 000H-
terminal (B12) peptide. The ability of these and smaller pep-
tides to inhibit Jurkat cell adhesion to substrates coated with
intact fibronectin was examined (Table I) . As we and others
(Humphries et al ., 1986, 1987 ; Garcia-Pardo et al ., 1990 ;
Guan and Hynes, 1990) have reported CS-1 was a potent in-
hibitor of cell adhesion to fibronectin (Table I) . Interestingly,
only the COOH-terminal B12 peptide was effective in in-
hibiting T cell adhesion to intact fibronectin (Table I) . This
is in agreement with our previously published findings with
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Table I. Molar Concentration ofCS-1 Peptides
Requiredfor50% Inhibition ofJurkat CellAdhesion
to Plasma Fibronectin
"Cr-labeled Jurkat cells (105/well) were incubated in the presence of the
varying concentrations (starting at 2 mg/ml) of the indicated peptides for 15
min . The Jurkat cells were then allowed to adhere toplasmafibronectin-coated
surfaces (5 ug/ml) in the presence of the peptides for 30 min . Adhesion to
fibronectin was evaluated as cpm bound to the fibronectin surface (Y axis),
plotted as a function ofmolar peptide concentration (X axis) and the 5056 inhi-
bition point was determined .
human B lymphocytes (Garcia-Pardo et al., 1990) and also
corroborates another report identifying the GPEILDVPST
as the active peptide for murine hematopoietic cell adhesion
(Guar and Hynes, 1990) . Next, a series of smaller peptides
derived from B12 were tested for their ability to inhibit Jur-
kat cell adhesion to intact fibronectin (Table 1) . The results
show clearly that deletion of the N112-terminal LHGP or
COOH-terminal PST residues had little effect on the ability
of a particularB12 derived peptide to inhibit Jurkat adhesion
to fibronectin . In fact, several of these truncated B12 pep-
tides (Table I) were similar in their ability to inhibit T cell
fibronectin interaction as long as the minimal EILDV se-
quence was conserved (Table I) . Interestingly, although LDV
has been reported to be the minimal peptide for the mela-
noma a4ß l receptor (Mould et al ., 1991 ; Komoriya et al.,
1991), LDV was not capable of inhibiting Jurkat-fibronectin
adhesion . The data in Table I suggest that the minimal pep-
tide ligand in CS-1 for the T lymphocyte a4ß1 receptor
is glu-iso-leu-asp-val or EILDV . Identical results were ob-
tained with aB lymphoblastoid cell line, Ramos (not shown)
and an identical pattern was observed for peptide inhibition
of Jurkat or Ramos cell adhesion to CS-1-coated surfaces ;
Table II . Molar Concentration ofCS-1 Peptide Conjugates
Requiredfor50% Adhesion ofJurkat Cells
Peptide or fragment
￿
Molar concentration
rsa-CS-1
rsa-B12
rsa-EILDVPST
rsa-EILDV
rsa-LDV
rsa-A13
49 1
115 .0
492 .0
1,007.0
1,129.0
>2,000.0
No adhesion
"Cr-labeled Jurkat cells (105/well) were incubated on surfaces coated with
varying concentrations of peptide-rsa conjugates starting at 50 ug/ml (wt/vol)
fragment or peptide (based on peptide not peptide-conjugate weight) . Adhesion
was evaluated as cpm bound to the surfaces (Y axis), plotted as a function of
fragment or peptide concentration (X axis) and the molar concentration of a
peptide required to support 5056 (oftotal input cpm) adhesion was calculated .
No adhesion, no measurable adhesion above negative controls .
Peptide Sequence Molar concentration
(MM)
CS-1 DELPQLVTLPHPNLHGPEILDVPST 0.18
B12 LHGPEILDVPST 0.40
GPEILDVPST 0.45
EILDVPST 0.55
LDVPST >1.60
VPST >2.50
EILDV 0.66
LDV >2.70
A13 DELPQLVTLPHPN >1 .00The Journal of Cell Biology, Volume 116, 1992
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Figure 3 . Adhesion of various hematopoetic cell lines to CS-1
(o) or LDV (®) -coated surfaces . "Cr-labeled Jurkat (T lympho-
blastoid), A375 (melanoma), U937 (monocytic), Ramos (B lym-
phoblastoid), and ST-1 (EBV transformedB lymphoblastoid) cells
were allowed to adhere to CS-1-rsa or LDVPSTrsa (51g/ml pep-
tide)-coated surfaces for 30 min at 37°C. At the end of this time
the nonadherent cells were washed offand the adherent cells were
solubilized inNaOH/SDS and quantitated in agammacounter. The
results are expressed as bound counts per minute.
deletion of the NHZ-terminal glutamic acid and isoleucine
residues resulted in a peptide with no inhibitory activity (not
shown) .
Minimal CS-1 FL-ptides Support Stable CellAdhesion
and Spreading
It wasof interest to determine if CS-1 or derivative peptides
were capable of inducing stable hematopoietic cell adhesion
andspreading . Therefore, RSA-peptideconjugates were pre-
paredand their ability to support cell adhesion wasexamined
and compared to intact fibronectin and fragments of fibro-
nectin containing theCTCBD (Table II and Figs. 2 and 3) .
As expected CS-1 andapeptide containingEILDVwere able
to support the adhesion of Jurkat and A375 melanoma cells
(Fig . 2, A and B) . Interestingly, peptide conjugates contain-
ing EILDV (Fig. 2 B) or LDV (not shown) also supported
melanoma cell spreading. However, on a molar basis there
were significant differences in the ability of CS-1 versus CS-1
derivative peptides to promote Jurkat cell adhesion (Table
II) . In general, truncated CS-1 peptides were inefficient
mediators of hematopoietic cell adhesion and none of the
truncated CS-1 peptide conjugates could support the adhe-
sion of PHA activated T cell blasts (not shown) . Further-
more, although the minimal peptide sequence required to
support melanoma cell adhesion has been reported to be
LDV (Mould et al ., 1991 ; Komoriya et al ., 1991) and, in our
hands, A375 melanoma cells didadhere to LDVPSTcoated
surfaces (Fig . 3), of the hematopoietic cell lines we exam-
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Figure 4 . Adhesion of Jurkat cells to surfaces coated with pFN-,
CS-1-, Al 3-, or B12-derived peptide-rsa conjugates in the presence
ofmAb 8A2 . (A)Adhesion in the presence ofpurified nonimmune
mouse IgG (5 ug/ml) . (B) Adhesion in the presence ofmAb 8A2
(5 Ag/ml) . 48-well plates were coated with 5 ug/ml (based on pep-
tide weight) peptide-rsa conjugates overnight in PBS at4°C . s'Cr-
labeled Jurkat cells were allowed to adhere to the peptide-coated
surfaces in the presence of IgGor 8A2 for30 min at 37°C. The rest
of the adhesion assayproceeded as for Fig . 3 . Results are expressed
as bound counts per minute .
ined only Jurkat cells adhered slightly to surfaces coated
with theLDVPSTrsaconjugate (Fig . 3) . Furthermore, some
of the hematopoietic cell lines we examined, such as U937
or ST-1 cells did not adhere to surfaces coated with intact
CS-1 (Fig . 3) . Thereason forthe apparent inability of some
cell populations to adhere to CS-1 or LDVPSTcoated sur-
faces wasnotimmediatelyobvious . Flow cytometry analysis
revealed that cell surface expression ofa4 or X31 could not
account for the functional differences we observed in the
ability ofa particular cell population to adhere to CS-1 or
LDVcoated surfaces . As we have previously reported (Way-
ner et al ., 1989) U937 (monocytic) and ST-1 (B lympho-
blastoid) cells express high levels of cell surface a4 and 01
Figure2 . Adhesion of Jurkat (A) or A375 melanoma cells (B) to plasma fibronectin (pFN), CS-1, A13, or EILDVPST-coated surfaces.
Plasma fibronectin (pFN) CS-1, A13, or EILDVPSTrsa conjugates were coated on virgin styrene surfaces (5 ug/ml) . The A375 or Jurkat
cells were allowed to adhere for 1 h. Nonadherent cells were washed off and the resulting monolayers were photographed with an inverting
microscope and phase contrast . These data show that A375 cells spread on surfaces coated with LDVcontaining peptides . Evidence of
Jurkat spreading can also be seen with CS-1 (A, top right) .M
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Activation ofthe a4ß1 Complex
Enhances Hematopoietic Cell Recognition
ofCS-1 Peptides
Figure 5. Adhesion of U937 cells to surfaces coated with pFN-,
CS-1-, Al3-, or B12-derived peptide-rsa conjugates in the presence
of mAb SA2 . (A) Adhesion in the presence of purified nonimmune
mouse IgG (5 pg/ml). (B) Adhesion in the presence of mAb 8A2
(5 jig/ml). 48-well plates were coated with 5 pg/ml (based on pep-
tide weight) peptide-rsa conjugates overnight in PBS at 4°C. "Cr-
labeled U937 cells were allowed to adhere to the peptide-coated
surfaces in the presence ofIgG or 8A2 for 30 min at 37°C. The rest
of the adhesion assayproceeded as for Fig. 3. Results are expressed
as bound counts per minute. U937 cells do not adhere to B12 pep-
tides without activation.
which are equivalent to the levels expressed by Jurkat and
A375 melanoma cells (Wayner et al., 1989). Together, the
data in Table II and Fig. 3 suggested that CS-1 or LDV
peptide recognition and binding might be regulated in a cell
type specific manner with melanoma cells possessing the
highest affinity receptor.
The results of the preceeding experiments suggested that
adhesion of cells to CS-1 might involve the LDV sequence
and that interaction of a4ß1 with this sequence outside the
context of intact CS-1 may be regulated in a cell-specific
manner. Several reports have suggested that the interaction
of cells with ECM proteins may require activation (Neuge-
bauer and Reichardt, 1991; Shimizu et al., 1990). Further-
more, we have recently described a mAb to ßl, SA2, that up-
regulates a4ß1-dependent lymphocyte adhesion to VCAM-1
494
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Figure 6. Adhesion of HUT 78 cells to surfaces coated with pFN-,
CS-1-, A13, or B12-derived peptide-rsa conjugates in the presence
ofmAb 8A2. (A) Adhesion in the presence ofpurified nonimmune
mouse IgG (5 /ig/ml). (B) Adhesion in the presence of mAb 8A2
(5 ug/ml). 48-well plates were coated with 5 vg/ml (based on pep-
tide weight) peptide-rsa conjugates overnight in PBS at 4°C. 5'Cr-
labeled HUT 78 cells were allowed to adhere to the peptide-coated
surfaces in the presence of IgG or SA2 for 30 min at 37°C. The rest
ofthe adhesion assay proceeded as for Fig. 3. Results are expressed
as bound counts per minute. Unlike U937 cells, HUT 78 cells ad-
here to LDVcoated surfaces without activation.
(Kovach et al., 1991) . Therefore, we examined the effects of
8,A2 on hematopoietic cell adhesion to CS-1 and derivative
peptides. These results are shown in Figs. 4 (Jurkat), 5
(U937 cells), and 6 (HUT 78). As can be seen from these
data Jurkat or U937 cells are capable ofmaximal interaction
with CS-1 and LDVcontaining derivative peptides only after
activation with the 8A2 mAb. U937 cells, in fact, do not ad-
here to any of the B12-derived peptides without activation.
Sincepretreatment ofcellswith 8A2 does not up-regulate ex-
pression of either 01 or a4 on U937 cells (not shown), these
data strongly suggest that recognition of the LDV sequence
by a4ß1 requires an activation signal which can be trans-
duced through01. As we have previously shown (Tàbles I and
II), VPSTrsa conjugates are inactive at inducing stable cell
adhesion (Figs. 4, 5, and 6) . These data strongly suggest that
the minimal essential adhesion sequence in CS-1 for acti-
vated hematopoietic cells is LDV. Interestingly, HUT 78
cells appeared to possess an active a4ß1 complex; resting
HUT 78 cells adhered to LDV and this adhesion was not
significantly up-regulated by 8A2 (Fig. 6).MONOCLONAL ANTIBODY
Figure 7. Adhesionof01 activated Jurkat or U937 cells to LDVPST
coated surfaces in the presence ofinhibitorymonoclonal antibodies
to a4 (P4C2) or 01 (P4C10). 5'Cr-labeled Jurkat (o) or U937 (®)
cells were pre-incubated with 84,2 for 30 min at 37°C. At the end
ofthis time, they were washed free ofunbound 8A2, and incubated
in the presence of nonimmune mouse IgG (]0 Pg/ml = Control)
or inhibitory mAbs to 01 (P4C10, 10 lzg/ml) or a4 (P4C2, 10
ttg/ml) on the LDVPSTrsa-coated surfaces for 30 min at 37°C.
Thus, the control as well as P4C10- or P4C2-treated cells were acti-
vated with 8A2 .
The adhesion of 8A2 activated Jurkat or U937 cells to
LDV peptide-coated surfaces couldbe completely abrogated
by inhibitory mAbs to a4 (P4C2) or ßl (P4C10) showing
clearly that it is the conjugate of a4 with ßl involved in LDV
adhesion (Fig. 7). We have previously shown that P400 and
8A2 recognize functionally distinct epitopes on ßl (Kovach
et al ., 1991): 8A2 stimulates ßl function and P4C10 inhibits
ßl function. Kinetic analysis ofßl activation by 8A2 revealed
that 8A2 induces rapid and stable U937 (or Jurkat) cell adhe-
sion to LDV peptide-coated surfaces. Within 5 min, sig-
nificant adhesion can be measured which peaks at 10-20
min. In some cell populations, such as Jurakat cells (not
shown) LDV recognition peaks within 5-min exposure to
8A2 . Since resting U937 cells do not adhere to LDVcoated
surfaces even after 90 min of incubation, these data clearly
indicate that the effects of 8A2 are not simply on the rate of
adhesion but are a function of altered LDV recognition pre-
sumably via an alteration in receptor conformation possibly
resulting in increased receptor avidity and LDV recognition.
Resting TLymphocytes Require Two Signals
for Adhesion to LDV
Interestingly, resting PBL did not adhere to CS-1 or LDV
coated surfaces even after pre-incubation with 8A2 (not
shown) . Peripheral blood-derived T lymphocytes required
prior activation with PHA (72-h culture) to interact with
LDVcoated surfaces in the presence of 8A2 (Fig. 9). As we
have previously reported, PHA activation does increase
a4ß1 expression on T lymphocytes (Wayner et al., 1989) .
However, treatment with 8A2 does not increase surface ex-
pression of either a4 or ßl on resting PBL or PHAactivated
T cell blasts (not shown) . Therefore, the effects of 8A2 on
LDV recognition by PHA-activated T lymphocytes cannot be
the result of increased a4ß1 expression. This strongly sug-
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Figure 8. Kinetic analysis of U937 cell adhesion to LDV
peptide-coated surfaces in the presence of mAb 84,2. "Cr-labeled
U937 cells (2 x 105) were applied to triplicate wells of separate
48-well plates (one for each timepoint) which had been coated with
5 ug/ml LDVPST-rsa. At time 0, 5 ug/ml-purified 8A2 was added
to the wells designated as activated (control wells to which51g/ml
nommmune mouse IgG was added were included for each time
point). Separate individualplates were harvested at each time point
as described above. The results are expressed as bound counts per
minute. In this experiment total cell input was 28,796 t 1,389.
Therefore, nearly maximal LDV-dependent adhesion was achieved
after 5-10 min activation with 8A2.
gests that resting PBL, unlike cultured hematopoietic cell
lines, require at least two signals for CS-1 (LDV) recogni-
tion, one of which is transduced through ßl (8A2) whilethe
other is transduced through the T cell receptor (PHA) .
Discussion
Recently, it has been shown by several laboratories that lym-
phocyte integrin receptors (reviewed by Springer, 1990) can
be activated to bind ligand with high avidity (Neugebauer
and Reichardt, 1991; Kovach et al., 1991). Activation ofinte-
grins in T lymphocytes can be achieved by cross-linking the
T cell receptor (Dustin and Springer, 1989; Shimizu et al.,
1990) or by mAbs to 01 (Kovach et al., 1992). Therefore,
we examined hematopoietic cell adhesion to CS-1 and
derivative peptides in the presence or absence of an antibody
known to activate 01 (Kovach et al ., 1992). Hematopoietic
cells which expressed the resting a4ß1 complex did not
recognize and bind LDV peptide. Such cell populations were
only able to bind LDV in thecontext ofCS-1 orin some cases
CS-1-B12 . However, after activating ßl with a mAb which
up-regulates ßl function (Kovach et al., 1992) the minimal
peptide ligand for the a4ß1 receptor in hematopoietic cells
was LDV. Furthermore, when the ßl complex was in the high
avidity state, the molar concentration of LDV peptide re-
quired to support stable cell adhesion was similar to intact
CS-1. We have previously shown that cross-linking of ßl by
8A2 is not required to up-regulate ßl-dependent function;
Fab fragments are as effective as intact antibody (Kovack et
al., 1992). Furthermore, we have also shown that 8A2 acti-
vation is energy dependent and does not result in the upregu-
lation of surface expression of a4 or ßl. Together these data
strongly suggest that the adhesion of some cell populations
to the LDV sequence in CS-1 is regulated in a cell-type
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Figure 9. Adhesion of 72 h PHA-stimulated T cell blasts to pFN,
CS4, A13, or B12 and derivative peptide-coated surfaces. (A)
Adhesion inthe presence ofpurified nonimmune mouse IgG (5 lg/
ml). (B) Adhesion in the presence ofmAb SA2 (5 ug/ml) . 48-well
plates were coated with 5 pg/ml (based on peptide weight) pep-
tide-rsa conjugates overnight in PBS at 4°C. 5'Cr-labeled PHA
blasts were allowed to adhere to the peptide-coated surfaces in the
presence ofIgG or8A2 for 30 minat 37°C. The rest ofthe adhesion
assayproceeded as forFig. 3. Results are expressed as boundcounts
per minute. Human PHA-stimulated T cell blasts were derived ex-
actly as previously described (Wayner et al., 1989).
specific manner and requires an activation signal transduced
through ßl.
Why some cells, such as Jurkat and Ramos, are able to
recognize and adhere to CS-1-coated substrates but not LDV
coated substrates without ßl activation is presently unclear.
There are several possible explanations for this. First, there
may be sequences in the NH2-terminal portion of CS-1 that
function to alter the conformation of the LDV sequence to
maximize a fit with the a4ß1-binding pocket. In this regard
it is interesting that the CS-1 sequence contains 5 proline and
5 leucine residues. This combination ofamino acids may re-
sult in folding of the CS-1 sequence so that the binding of
LDV to a4ß1 is optimized. Since soluble Al3 peptide does
not enhance LDV recognition by Jurkat cells, this argues
against a steric role for A13 in promoting LDV binding. In
addition, since cells do not adhere to the A13 peptide even
after ßl activation this argues against a direct role for this
peptide in promoting cell adhesion.
A second possibility may be more likely. There may be se-
quences in the N112-terminal portion of CS-1 which func-
tion to strengthen or "lock" the LDV peptide sequence into
the a4ß1-binding pocket after the initial attachment event.
This has been reported to occur for avß3 and the RGD se-
quence in vitronectin (Orlando and Cheresh, 1991). Prece-
dence for this notion also comes from the work of Obara et
al. (1988) in which a second site in the CCBD of fibronectin
has been shown to act synergistically with the RGDS site in
promoting cell adhesion and spreading. These "strengthen-
ing" or "synergistic sequences in ligands may perform ex-
actly the same function as the activating 8A2 antibody and
alterreceptor avidity by influencing the conformation of ßl.
A model for this type ofinteraction can easily be envisioned.
The ligand (in this case LDV)-binding pocket is created by
a complex of a and ß (cations may also be involved) . The
LDV peptide binds to the receptor, this in turn may then im-
mediately alterthe conformation ofthe receptor such that the
secondary "strengthening" or "synergy" site in ßl engages to
"lock" the receptor onto the ligand. It is this engagement
which may define the high-avidity state. Cells such as HUT
78 and A375 melanoma may possess a permanently engaged
receptor whileJurkat and Ramos cellspossess a partially en-
gaged receptor. This "locking" mechanism may also involve
the transduction of a signal through ßl. The inhibitory anti-ßl
mAb, P4C10, interfereswith adhesion by inhibitingLDVbind-
ing. The activating anti-ßl mAb, 8A2, functions by mimick-
ing the "strengthening" site. These distinct sites in ßl act in
concert to promote adhesion to any given ligand. Ligand
specificity is therefore determined by a and both sites in ßl
being engaged simultaneously. The concept of "binding" or
"strengthening" sitesbeingindependently regulated provides
an exquisitely dynamic system of checks and balances.
In conclusion, the present studies identify the LDV tripep-
tide as the minimal adhesive peptide in the CS-1 portion of
the V region of fibronectin. However, only cells which ex-
press the high-avidity form of the receptor bind LDV coated
surfaces. The high-avidity state of the receptor can be in-
duced by preincubating cells with an activating mAb to ßl
(8A2). 8A2 activation of ßl was rapid and did not result in
an increase in cell surface ßl expression. Resting peripheral
blood T cellscouldnot be induced by 8A2 to bind LDV while
PHA stimulated T cell blasts could be. This implies that
LDV recognition by normal T cells requires at least two sig-
nals, one of which is transduced through the T cell receptor
(PHA activation) and the other which is transduced via the
integrin ,ßl subunit (8A2). Furthermore, since resting T
cells, PHA blasts, HUT 78, and Jurkat cells do not demon-
strate the same pattern and levelofCS-1 peptide recognition,
this suggests that malignant or activated T cells express
receptor complexes that vary in terms of basal a4ß1 activa-
tion. The significance ofthis with regard to malignant T lym-
phocyte transformation and infiltration of organs such as the
skin in neoplastic or chronic inflammatory disease has yet
to be determined.
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